Remdesivir snags Canadian OK To view this email as a web page,
click here Pfizer, BioNTech start their COVID-19 vax phase 3, squaring off with Moderna GOP relief bill gives providers liability protection, another $25B Biopharma roundup: Remdesivir nabs Canadian COVID-19 OK; Pfizer shot could tee up $15B sales, analyst says UHS generates $251M in profits thanks to help from COVID-19 relief funds Healthcare roundup: COVID-19 hospitalizations cost Medicare $2.8B, CMS says Vyndaqel, Ibrance boost Pfizer as it eyes COVID-19 vaccine launch this year Neidorff: Centene planning for COVID-19 to linger well into 2021 Covance revenue hit hard as COVID-19 continues to drag on trial services Featured Story | By Ben Adams Pfizer and German biotech partner BioNTech have on the same day as rival Moderna kick-started a late-stage effort for their “best” attempt at an mRNA pandemic vaccine. read more |
| |
|---|
|
Top Stories By Robert King Senate Majority Leader Mitch McConnell released a new COVID-19 legislative package that includes liability protection for providers. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Canada granted conditional approval to Gilead's remdesivir in severe COVID-19. Pfizer could earn $15 billion-plus from its COVID-19 vaccine, one analyst thinks; meanwhile, the pharma ratcheted up its 2020 sales projections, vaccine not included. A vaccine distribution initiative weighs tiered pricing for equitable shot access. Plus, a new viral mutation could boost vaccine efficacy. read more By Robert King Federal stimulus funds helped Universal Health Services generate $251 million in profit in the second quarter and offset major declines in revenue due to COVID-19. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Angus Liu Add another name to the list of pharmas reporting sales declines amid the pandemic. But this company, Pfizer, is still dialing up its full-year revenue expectations—not that it’s counting any contribution from a closely watched COVID-19 vaccine candidate it’s hoping to launch this year. read more By Paige Minemyer Centene Corporation earned $1.21 billion in profit for the second quarter. That's a significant boost from the $495 million in profit it reported in the second quarter of 2019. read more By Ben Adams Covance’s sales fell into the red this quarter as LabCorp’s CRO unit continues to battle major pandemic headwinds. read more |
|
